Solid Tumor Cancer Personalized Medicine Therapies Form New Treatment Approach.

Share Article

Medmeme, LLC. reports high level of new research and development by pharmaceutical firms partnering with smaller biotech firms evidenced in medical meeting presentations.

News Image

The new syndicated TrendsmemeTM Report: Oncology – Solid Tumors has been released by Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms. The report details the trends and drug development/market potential for the pharmaceutical industry particularly focusing on the following four disease indications (with estimated 2012 cases/deaths indicated): breast cancer (290,000/40,000), NSCLC (non-small-cell lung cancer)(226,000/160,000), pancreatic cancer (44,000/37,000), and melanoma (760,000/9,000). The National Cancer Institute (NCI) projects that in 2012, more than 1,550,000 people in the United States will be diagnosed with a malignant tumor and further estimates that the direct cost for all these solid tumor types in the United States alone will be $124.6 billion.

Between 2009 and 2011 seven new drugs were FDA approved in the United States for treatment of the four solid tumor types. According to, another 25 to 30 new cancer drug products are being developed for various solid tumor indications and are expected to be FDA approved within the next two to four years. The most successful and promising tumor treatment regimens are based on targeted therapies for patients who have molecular abnormalities and/or chromosomal rearrangements. This personalized medicine approach represents a paradigm shift in oncology treatment. The most active companies in new treatment development are: Pfizer, Novartis, Roche, GlaxoSmithKline, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Amgen, Boehringer Ingelheim, Eisai, and Merck. The new approach has fostered strategic partnerships between small biotech and large pharma firms, including CureTech and Teva, Forma Therapeutics and Genentech, Epizyme, with Eisai and GlaxoSmithKline, and Aveo Pharmaceuticals with Merck, Astellas Pharma, Biogen Idec, and Johnson & Johnson. Other firms with notable R&D under way in the category include Altor, BioScience, Celldex Therapeutics, Endocyte, MannKind, and Neogenix Oncology.

Medmeme CEO Mahesh Naithani describes the high interest level in oncology research: “From the 2009 to 2011 information in our database on the oncology research presented at medical meetings, and this is represented in the abstracts we have available, there is a clear demonstration that advances in treating these four tumor type cancers has stimulated a great deal of interest among scientists and clinicians alike. For breast cancer, respectively, the number of these presentations were 2,462, 2,523, and 2,572, with about half at the top ten meetings. For NSCLC they were 900, 730, and 1,030. For pancreatic cancer they were 279, 117, and 301. And for melanoma they were 515, 479, and 453, again with about half at the top 10 meetings. Any way you look at it this represents a tremendous amount of research and development for oncology, which in turn reflects the shift toward many therapeutic regimens based on combination therapies commonly entailing multiple drugs, each drug offering a distinct mechanism of action. The report defines who is doing what, and where, in this research.”

The syndicated TrendsmemeTM Report: Oncology – Solid Tumors can be purchased separately, or, along with other MedMeme reports in the new ten report series, at discounted pricing. To learn more, contact Medmeme, or see the website,

Medmeme, LLC                                                                             
Yan Barshay, Executive Vice President                 
+1 212-725-5992                                


Ray Wright, Vice President, Sales
+ 1 508-278-4595

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Yan Barshay

Raymond Wright
MedMeme LLC
Email >
Visit website